Enlivex Therapeutics Ltd (ENLV)

07:15 AM

Is Enlivex Therapeutics Ltd. a good long term investmentExplosive earnings growth - jammulinksnews.com

07:15 AM

03:57 AM

Enlivex Therapeutics Ltd. Stock Analysis and ForecastUnprecedented profits - jammulinksnews.com

03:57 AM

Jul 20, 2025

What drives Enlivex Therapeutics Ltd. stock priceOutstanding capital returns - Autocar Professional

Jul 20, 2025

Jul 20, 2025

What analysts say about Enlivex Therapeutics Ltd. stockExtraordinary market timing - Autocar Professional

Jul 20, 2025

Jul 16, 2025

why enlivex therapeutics ltd. stock attracts strong analyst attentionLow Risk Entry Points - Newser

Jul 16, 2025

Jul 16, 2025

Why Enlivex Therapeutics Ltd. stock attracts strong analyst attentionReal Trader Insights - beatles.ru

Jul 16, 2025

Jul 16, 2025

How Enlivex Therapeutics Ltd. stock performs during market volatilityPrecision Entry Strategy - Newser

Jul 16, 2025

Jul 15, 2025

What makes Enlivex Therapeutics Ltd. stock price move sharplyReturn Maximized Portfolio Strategy - Newser

Jul 15, 2025

Jun 17, 2025

Sepsis Market Growth to Accelerate in Forecast Period - openPR.com

Jun 17, 2025

Jun 13, 2025

Enlivex Therapeutics and Foremost Clean Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Daily Jeffersonian

Jun 13, 2025

Jun 13, 2025

Trust Consulting Services CEO James Radford Named One of CIO Bulletin's "Best Entrepreneurs to Watch 2025" - Marco Eagle

Jun 13, 2025

Jun 13, 2025

Unusual Machines Announces Termination of Definitive Agreement to Acquire Aloft - The Holland Sentinel

Jun 13, 2025

Jun 13, 2025

Safe 'N' Sound Environmental Services Ltd. Recognized with 2025 Consumer Choice Award for Asbestos Removal in Halton Region - Sarasota Herald-Tribune

Jun 13, 2025

Jun 11, 2025

Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025 - IndyStar

Jun 11, 2025

Jun 10, 2025

Enlivex Therapeutics (ENLV) to Present Promising Allocetra Data at EULAR Congress | ENLV Stock News - GuruFocus

Jun 10, 2025

Jun 10, 2025

Enlivex Therapeutics to Present Clinical Data of Allocetra in Os - GuruFocus

Jun 10, 2025

Jun 10, 2025

Enlivex Therapeutics Ltd. to Present Allocetra™ Data at EULAR 2025 Congress in Barcelona - Nasdaq

Jun 10, 2025

Jun 10, 2025

Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology - The Manila Times

Jun 10, 2025

Jun 10, 2025

Breakthrough Cell Therapy Shows Promise in Knee Osteoarthritis: Enlivex Phase I/II Trial Data at EULAR 2025 - Stock Titan

Jun 10, 2025

Jun 10, 2025

Interactive Strength Inc. (Nasdaq: TRNR) Updates FAQ's about Increasing 2025 Pro Forma Revenue Guidance to More Than $75M and Other Questions - Reno Gazette Journal

Jun 10, 2025

Jun 07, 2025

Millennium Management LLC Acquires New Holdings in Enlivex Therapeutics Ltd. (NASDAQ:ENLV) - Defense World

Jun 07, 2025

Jun 06, 2025

Enlivex Therapeutics (ENLV) to Release Quarterly Earnings on Friday - Defense World

Jun 06, 2025

Jun 02, 2025

Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform - El Paso Times

Jun 02, 2025

May 30, 2025

Enlivex Reports Q1 2025 Financial Results with Reduced Loss - TipRanks

May 30, 2025

May 29, 2025

D. Boral Capital Acted as Sole Bookrunner to Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) in connection with its $13.5 Million Initial Public Offering - Lohud

May 29, 2025

May 29, 2025

Enlivex Therapeutics (NASDAQ:ENLV) Shares Down 4% – Time to Sell? - Defense World

May 29, 2025

May 28, 2025

MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program - El Paso Times

May 28, 2025

May 21, 2025

ENLIVEX THERAPEUTICS Earnings Preview: Recent $ENLV Insider Trading, Hedge Fund Activity, and More - Nasdaq

May 21, 2025

May 20, 2025

Enlivex (ENLV) to Present Cell Therapy Advancements at Israeli B - GuruFocus

May 20, 2025

May 20, 2025

Revolutionary Cell Therapy Shows 47% Pain Reduction in Osteoarthritis: Enlivex Reveals Breakthrough Data - Stock Titan

May 20, 2025

May 20, 2025

Enlivex Selected to Present at Israeli BioMed 2025 Conference - FinancialContent

May 20, 2025

May 08, 2025

Sheba Medical Center and Enlivex Announce Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers - Barchart.com

May 08, 2025

May 07, 2025

Renaissance Technologies LLC Acquires 84,203 Shares of Enlivex Therapeutics Ltd. (NASDAQ:ENLV) - Defense World

May 07, 2025

May 02, 2025

Enlivex Receives Regulatory Authorization From Israel’s Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis - ACCESS Newswire

May 02, 2025

Apr 24, 2025

Enlivex stock holds Buy rating with $7 target from H.C. Wainwright - Investing.com India

Apr 24, 2025

Apr 23, 2025

Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoa - GuruFocus

Apr 23, 2025

Apr 23, 2025

Enlivex to Present Allocetra™ Insights at OARSI 2025 - TipRanks

Apr 23, 2025

Apr 23, 2025

Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress - The Manila Times

Apr 23, 2025

Apr 23, 2025

Enlivex Therapeutics to Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World ... - Bluefield Daily Telegraph

Apr 23, 2025

Apr 23, 2025

Enlivex Therapeutics to Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World Congress - TradingView

Apr 23, 2025